Yuce Biotech raises $7.4M Series B for single-molecule immunodiagnostics

What's the deal? Yuce Biotech has raised more than 50,000,000 CNY (about $7.4 million) in a Series B round, the Chinese diagnostics company announced in September 2026. The round was led by the Jiangsu Taizhou Big Health Advanced Manufacturing Industry Special Fund of Funds.

Who backed it? Shanghai Universal Biotech Co., Ltd. participated as a follow-on investor. Existing backer Linghang Xinjie Capital added to its stake in the round.

What's the endgame? Yuce Biotech develops and manufactures next-generation single-molecule immunodiagnostic technology. It describes itself as the first company in China to commercialise the approach at scale.

The signal: Backing from a state-linked advanced manufacturing fund points to policy support for domestic diagnostics capacity, and the round adds fresh capital to a niche where Chinese firms are moving to build homegrown alternatives to imported technology.

Image credit: USFWS Mountain Prairie